Cargando…

Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases

Cardiovascular disease (CVD), the number one cause of death worldwide, has always been the focus of clinical and scientific research. Due to the high number of deaths each year, it is essential to find alternative therapies that are safe and effective with minimal side effects. Traditional Chinese m...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Yu-Qing, Chen, Heng-Wen, Li, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507407/
https://www.ncbi.nlm.nih.gov/pubmed/32982178
http://dx.doi.org/10.2147/DDDT.S272355
_version_ 1783585221569937408
author Tan, Yu-Qing
Chen, Heng-Wen
Li, Jun
author_facet Tan, Yu-Qing
Chen, Heng-Wen
Li, Jun
author_sort Tan, Yu-Qing
collection PubMed
description Cardiovascular disease (CVD), the number one cause of death worldwide, has always been the focus of clinical and scientific research. Due to the high number of deaths each year, it is essential to find alternative therapies that are safe and effective with minimal side effects. Traditional Chinese medicine (TCM) has a long history of significant impact on the treatment of CVDs. The mode of action of natural active ingredients of drugs and the development of new drugs are currently hot topics in research on TCM. Astragalus membranaceus is a commonly used Chinese medicinal herb. Previous studies have shown that Astragalus membranaceus has anti-tumor properties and can regulate metabolism, enhance immunity, and strengthen the heart. Astragaloside IV (AS-IV) is the active ingredient of Astragalus membranaceus, which has a prominent role in cardiovascular diseases. AS-IV can protect against ischemic and hypoxic myocardial cell injury, inhibit myocardial hypertrophy and myocardial fibrosis, enhance myocardial contractility, improve diastolic dysfunction, alleviate vascular endothelial dysfunction, and promote angiogenesis. It can also regulate blood glucose and blood lipid levels and reduce the risk of cardiovascular diseases. In this paper, the mechanism of AS-IV intervention in cardiovascular diseases in recent years is reviewed in order to provide a reference for future research and new drug development.
format Online
Article
Text
id pubmed-7507407
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-75074072020-09-24 Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases Tan, Yu-Qing Chen, Heng-Wen Li, Jun Drug Des Devel Ther Review Cardiovascular disease (CVD), the number one cause of death worldwide, has always been the focus of clinical and scientific research. Due to the high number of deaths each year, it is essential to find alternative therapies that are safe and effective with minimal side effects. Traditional Chinese medicine (TCM) has a long history of significant impact on the treatment of CVDs. The mode of action of natural active ingredients of drugs and the development of new drugs are currently hot topics in research on TCM. Astragalus membranaceus is a commonly used Chinese medicinal herb. Previous studies have shown that Astragalus membranaceus has anti-tumor properties and can regulate metabolism, enhance immunity, and strengthen the heart. Astragaloside IV (AS-IV) is the active ingredient of Astragalus membranaceus, which has a prominent role in cardiovascular diseases. AS-IV can protect against ischemic and hypoxic myocardial cell injury, inhibit myocardial hypertrophy and myocardial fibrosis, enhance myocardial contractility, improve diastolic dysfunction, alleviate vascular endothelial dysfunction, and promote angiogenesis. It can also regulate blood glucose and blood lipid levels and reduce the risk of cardiovascular diseases. In this paper, the mechanism of AS-IV intervention in cardiovascular diseases in recent years is reviewed in order to provide a reference for future research and new drug development. Dove 2020-09-15 /pmc/articles/PMC7507407/ /pubmed/32982178 http://dx.doi.org/10.2147/DDDT.S272355 Text en © 2020 Tan et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Tan, Yu-Qing
Chen, Heng-Wen
Li, Jun
Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
title Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
title_full Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
title_fullStr Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
title_full_unstemmed Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
title_short Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases
title_sort astragaloside iv: an effective drug for the treatment of cardiovascular diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507407/
https://www.ncbi.nlm.nih.gov/pubmed/32982178
http://dx.doi.org/10.2147/DDDT.S272355
work_keys_str_mv AT tanyuqing astragalosideivaneffectivedrugforthetreatmentofcardiovasculardiseases
AT chenhengwen astragalosideivaneffectivedrugforthetreatmentofcardiovasculardiseases
AT lijun astragalosideivaneffectivedrugforthetreatmentofcardiovasculardiseases